NCT06620627 Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection
| NCT ID | NCT06620627 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Natera, Inc. |
| Condition | Colorectal Cancer Screening |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2024-01-26 |
| Primary Completion | 2025-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2024-01-26 with a primary completion date of 2025-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The PROCEED-CRC study will prospectively collect blood samples from participants who are at average risk of colorectal cancer (CRC). Samples will be used for research use and the development of a blood-based CRC screening test.
Eligibility Criteria
Inclusion Criteria: 1. 40 years of age or older at time of consent. 2. Planning or intending to undergo asymptomatic screening colonoscopy. 3. Able to tolerate venipuncture for research draw(s). 4. Able and willing to provide blood samples within the 120 days prior to a colonoscopy procedure. 5. Willing and able to comply with the study visit schedule and study requirements. 6. Signed informed consent(s) must be obtained prior to participation in the study Exclusion Criteria: 1. Any prior history of any kind of malignancy (exception: participants who have undergone surgical removal of skin squamous cell or basal cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study) 2. Had a complete colonoscopy with adequate bowel preparation in the previous nine (9) years. 3. Undergoing diagnostic colonoscopy for investigation of symptoms such as unexplained and long-lasting diarrhea, overt rectal bleeding, e.g., hematochezia or melena, within the previous 30 days. (Blood on toilet paper, after wiping, does not constitute rectal bleeding) 4. Undergone colorectal cancer screening within the associated recommended intervals 1. FOBT/FIT within the previous 12 months 2. FIT-DNA test within the previous 36 months 3. Blood-based CRC screening test within the previous 36 months 4. Computed tomography colonography CTC within the previous 5 years 5. Flexible sigmoidoscopy within the previous 5 years 5. Precancerous findings on most recent colonoscopy. This does not include benign, and/or hyperplastic polyps of any size (Note: Tissue biopsies that result in no histopathology findings are acceptable) 6. Had a prior colorectal resection for any reason other than sigmoid diverticular disease 7. Diagnosis or personal history of any of the following high-risk conditions for colorectal cancer: 1. Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohns disease 2. Familial adenomatous polyposis (also referred to as FAP, including attenuated FAP) 3. Hereditary non-polyposis colorectal cancer syndrome (also referred to as HNPCC or Lynch Syndrome) 4. Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardners Syndrome, Turcots (or Crails) Syndrome, Cowdens Syndrome, Juvenile Polyposis, Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06620627 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Colorectal Cancer Screening. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06620627 currently recruiting?
Yes, NCT06620627 is actively recruiting participants. Contact the research team at proceedcrc@natera.com for enrollment information.
Where is the NCT06620627 trial being conducted?
This trial is being conducted at Austin, United States.
Who is sponsoring the NCT06620627 clinical trial?
NCT06620627 is sponsored by Natera, Inc.. The trial plans to enroll 5,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.